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Abstract. The aim of this study was to develop a drug-speciﬁc absorption model for gliclazide (GLK)
using mechanistic gastrointestinal simulation technology (GIST) implemented in GastroPlusTM software
package. A range of experimentally determined, in silico predicted or literature data were used as input
parameters. Experimentally determined pH-solubility proﬁle was used for all simulations. The human
jejunum effective permeability (Peff) value was estimated on the basis of in vitro measured Caco-2
permeability (literature data). The required PK inputs were taken from the literature. The results of the
simulations were compared with actual clinical data and revealed that the GIST-model gave accurate
prediction of gliclazide oral absorption. The generated absorption model provided the target in vivo
dissolution proﬁle for in vitro–in vivo correlation and identiﬁcation of biorelevant dissolution
speciﬁcation for GLK immediate-release (IR) tablets. A set of virtual in vitro data was used for
correlation purposes. The obtained results suggest that dissolution speciﬁcation of more than 85% GLK
dissolved in 60 min may be considered as “biorelevant” dissolution acceptance criteria for GLK IR
tablets.
KEY WORDS: biorelevant dissolution speciﬁcation; gliclazide; in vitro–in vivo correlation (IVIVC);
mechanistic absorption simulation.
INTRODUCTION
Gliclazide (GLK) is a second-generation sulfonylurea
derivative, widely used for the treatment of type II diabetes
mellitus. GLK is available as oral tablets (30 and 80 mg
strength) with the recommended dosage between 40 and
320 mg/day. Reports from the in vivo studies show that, after
oral administration, gliclazide is almost completely absorbed
(1,2). However, due to its low and pH-dependent aqueous
solubility (3–5), GLK absorption rate appears to be slow and
variable (3,6–8), and therefore, its absorption proﬁle is
difﬁcult to decipher.
Drug absorption and sufﬁcient and reproducible bio-
availability are recognized as some of the major issues
considering drug delivery from solid oral dosage forms. In
order to establish the relationship between drug physico-
chemical data and its clinical performance, a mechanistic
approach to oral drug absorption based on the Biopharma-
ceutics Classiﬁcation System (BCS) was introduced (9).
According to the BCS concept, drug dose solubility and
dissolution rate from pharmaceutical preparations along with
intestinal permeability are major determinants of its absorp-
tion. Oral absorption of ionizable poorly water-soluble drugs
(BCS class II weak electrolytes) is inﬂuenced by both their
physicochemical properties and physiological conditions in
the gastrointestinal (GI) tract (e.g., pH and the presence of
surfactants). Although characterized by low aqueous solubil-
ity, these drugs often show high bioavailability after oral
administration.
Oral drug absorption is usually estimated from the in vivo
plasma concentration (Cp)–time data following intra- and
extravascular drug inputs by means of conventional pharmaco-
kinetic (PK) methods (numerical deconvolution, Wagner
Nelson, Loo Riegelman). However, if intravenous data are
lacking due to poor drug solubility and/or if the drug shows
nonlinear kinetics, this might present a limitation for conven-
tional pharmacokinetic analysis. Development of the in silico
prediction tools capable of forecasting in vivo absorption solely
on the basis of drug physicochemical and PK properties has
therefore received widespread attention over the past few years
(10–14). Based on the theory of the BCS and GI physiology, a
semiphysiological absorption model named Advanced Com-
partmental Absorption and Transit model (ACAT; commer-
cially available as GastroPlusTM software package) for in silico
prediction of oral drug absorption was developed. The form of
ACAT model implemented in GastroPlus is modeled by a
system of coupled linear and nonlinear rate equations used to
simulate the effect of physiological conditions on drug
absorption as it transits through successive GI compartments.
The equations include the consideration of six states (unreleased,
undissolved, dissolved, degraded, metabolized, and absorbed), 18
compartments (stomach, seven compartments for the small
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intestine, colon, and nine enterocyte compartments), three
states of excreted material (unreleased, undissolved, and
dissolved), and the amount of drug in up to three PK
compartments (when PK parameters are available). The
total amount of absorbed material is summed over the
integrated amounts being absorbed/exsorbed from each
absorption/transit compartment (12). Besides physiological
parameters, this model requires certain input parameters
regarding drug physicochemical and PK data along with
some product characteristics. Such parameters should
adequately reﬂect drug biopharmaceutical properties.
The most commonly used drug physicochemical property
to assess its in vivo performance is in vitro dissolution of a
drug product. It is, therefore, important to deﬁne drug release
methodology that would be predictive of its clinical perform-
ance and to establish quantitative in vitro–in vivo correlation
(IVIVC). Validated IVIVC model, and consequently, identi-
ﬁcation of biorelevant dissolution method can aid in reducing
the number of human in vivo studies during the development
of generic formulations, their approval by the regulatory
agencies, and certain post-approval changes.
The purpose of this study was: (1) to develop a drug-
speciﬁc absorption model for gliclazide using gastrointestinal
simulation technology (GIST), (2) to use the generated
absorption model to provide the target in vivo dissolution
proﬁle for IVIVC, and (3) to identify biorelevant dissolution
speciﬁcations for GLK IR tablets based on a set of virtual in
vitro data. Level A IVIVC based on deconvolution and
convolution approaches were applied to assess the relationship
between the in vitro and in vivo data. Dissolution acceptance
criteria were discussed in terms of the extent in which the
differences in drug release kinetics observed in vitro were
reﬂected on the simulated in vivo dissolution proﬁle.
MATERIALS AND METHODS
In Vivo Data
The pharmacokinetic inputs required for the simulation,
calculated on the basis of the actual clinical data, were taken
from the literature (7). Published data from gliclazide
bioequivalence (BE) studies (Diamicron® 80 mg IR tablets)
(2) were used to evaluate the resultant gliclazide absorption
model. These data were also used for in vitro–in vivo
correlation purposes.
In Vitro Studies
Solubility Determination. Equilibrium solubility was
determined by a “shake-ﬂask” method using various
buffer media in the pH range 1.1–9.0. Excess amount of
gliclazide powder (Zhejiang Jiuzhou Pharmaceutical Co.
Ltd., China) was placed into the vials containing 40 mL of
each tested media and shaken at 250 rpm for 48 h at 37±
0.5°C. Samples withdrawn were ﬁltered, properly diluted,
and assayed for gliclazide UV spectrophotometrically
(Evolution 300, Thermo Fisher Scientiﬁc, UK) at the
wavelength of the relative maximum absorption. All
measurements were performed in triplicate.
Dissolution Studies. Dissolution studies of 80-mg
generic gliclazide IR tablets commercially available on
Serbian market (Glioral, Galenika a.d., Serbia; Glikosan,
Slaviamed, Serbia; and Diprian, Hemofarm a.d., Serbia)
were carried out in a rotating paddle apparatus (Erweka
DT 70, Germany) at 37±0.5°C and rotational speed of
100 rpm, using 900 ml of various dissolution media (media
pH 1.2, 4.0, 4.5, 6.8, 7.2, and 7.4). Withdrawn samples
were ﬁltered and after appropriate dilution, assayed for
gliclazide UV spectrophotometrically at the wavelength of
the relative maximum absorbance.
Experimental in vitro data for 80-mg generic GLK
tablets and literature in vitro data for Diamicron® 80-mg
GLK tablets (3) were used to construct a set of virtual in
vitro data used for GastroPlusTM simulation. The
investigated in vitro proﬁles were generated to reﬂect the
situation where less than 85% of the drug is dissolved
(incomplete dissolution because of limited GLK solubility
in the pH range 3.0–4.2; proﬁle a); more than 85% of the
drug is dissolved in 15 (“very rapid” dissolution criteria;
proﬁle e), 30 (“rapid” dissolution criteria; proﬁle d), 45
(proﬁle c), or 60 min (proﬁle b).
Mechanistic Simulations
GastroPlusTM (version 6.1.0003, Simulations Plus, Inc.,
Lancaster, CA, USA) was used to simulate the in vivo
absorption proﬁle of gliclazide. The program has three
input tabs, namely Compound, Physiology, and
Pharmacokinetics, comprising three sets of factors
inﬂuencing oral drug absorption. The required input
parameters related to gliclazide physicochemical and
pharmacokinetic propert ies were experimental ly
determined, in silico predicted and/or taken from the
literature. Summary of the input parameters used is given
in Table I. Considering controversial literature data
regarding gliclazide solubility (3,5), experimentally
determined pH-solubility proﬁle was employed for all
simulations. For drug absorption simulation based on
GLK physicochemical and PK data, the “IR tablet mode”
was speciﬁed; when in vitro dissolution proﬁles of IR GLK
tablets were used as an input function in GastroPlusTM, the
“tabulated in vitro dissolution data” function together with
the “CRU-dispersed” dosage form was selected.
In the Physiology tab, the Opt logD Model SA/V 6.1
was used to estimate the changes in permeability as drug
travels along the GI tract. The absorption gradient
coefﬁcients C1–C4 were adjusted (using the Optimization
module) to best match the resultant model to the
experimental data. These coefﬁcients were used to calcu-
late the absorption scale factors (ASF) which scale the
effective permeability to account for variations in absorption-
rate-determining effects (e.g., pH effects, the presence of
inﬂux and efﬂux transporters) that differ from one
compartment to another (12). All other parameters were
ﬁxed at default values that represent human fasted
physiology.
Parameter sensitivity analysis (PSA) was used to assess
the effect of input PK parameters (systemic clearance, volume
of distribution, ﬁrst-pass effect) on the predicted rate and
extent of GLK absorption.
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Numerical Convolution. A set of virtual in vitro data
representing different dissolution scenarios was used as the
input function in GastroPlusTM software to estimate the
expected GLK in vivo absorption proﬁles. The proﬁles
obtained were compared with the mean plasma
concentration proﬁle of gliclazide observed after oral
administration of 80-mg tablets (2).
Numerical Deconvolution. In the deconvolution
approach, the percent of drug absorbed at the speciﬁed time
points estimated by GastroPlusTM was plotted against the
percent dissolved in vitro at the same time points. Time
scaling factor was taken into account considering the time
discrepancies between the in vitro and in vivo release proﬁles.
Linear regression analysis was used to evaluate the
obtained correlation plots.
RESULTS AND DISCUSSION
Solubility
The experimentally obtained solubility data indicate that
gliclazide is an ampholyte with pH-dependent solubility in the
GI pH range (Fig. 1).
According to the BCS (15), GLK meets the criteria of a
low solubility drug. Regarding the conservative criterion for
the upper limit of dose number (D0=1), solubility is expected
to be the limiting factor for GLK absorption up to pH 6.9. In
order to determine the solubility-limited region for GLK in a
more accurate way, the critical dose number value for GLK
was calculated using the equation (Eq. 1) that relates the
extent of drug absorption to its dose number, assuming the
drug is highly permeable (9):
F ¼ 2 An
D0
ð1Þ
where F is the fraction of drug absorbed, and An is the
absorption number calculated by GastroPlusTM (An=7.27).
The critical value of D0 was calculated under the assumption
that the drug is completely absorbed (F=1).
Regarding the obtained D0 value (D0>14.5), pH 3.0–
4.2 can be considered as a solubility-limited region of
GLK absorption. Above the pH 4.2 boundary, gliclazide
solubility markedly increased, indicating that solubility is
not the limiting factor for the absorption throughout the
intestine. Therefore, GLK might be classiﬁed as intermediate
solubility drug with non-solubility-limited absorption after
oral administration.
Mechanistic Simulation–Model Validation
Gastrointestinal simulation for GLK IR tablets based on
the input parameters presented in Table I was performed
using the GastroPlusTM Single Simulation Mode. The
simulated GLK absorption proﬁle is presented in Fig. 2,
together with the mean plasma proﬁle taken from the
literature (2).
The predicted fraction of drug absorbed (Fa) was 99.94%
which is in accordance with the literature-reported almost
100% bioavailability of gliclazide after oral administration
(1,2). The predicted and in vivo observed pharmacokinetic
parameters following oral administration of 80-mg GLK IR
tablets are shown in Table II. The percent prediction error
values were less than 10% for Cmax and area-under-the-curve
values indicating that the generated absorption model gave
Fig. 1. pH-dependent solubility of gliclazide at 37±0.5°C and
calculated dose numbers (D0) for 80 mg gliclazide dose. Dotted lines
represent the critical dose numbers for GLK (conservative upper
limit of D0=1, and the calculated value of D0=14.5)
Table I. Summary of the GLK Input Parameters Employed for
Gastrointestinal Simulation
Parameter Value
Molecular weight 323.4 g/mol
log P 1.448a
pKa 2.9; 5.8; 9.6b
Human jejunal permeability 3.683×10−4 cm/sc
Dose 80 mg
Dose volume 250 ml
Solubility (pH 4.37) 0.025 mg/mld
Mean precipitation time 900 se
Diffusion coefﬁcient 0.782×10−5 cm2/sa
Drug particle density 1.2 g/mle
Effective particle radius 25 μme
Body weight 74 kg
FPE (liver) 30%f
Blood/plasma conc. ratio 1e
Unbound percent in plasma 4.7%f
CL 0.012 L/h/kgf
Vc 0.23 L/kg
f
Elimination half-life, t1/2 13.29 h
Simulation time 48 h
GLK gliclazide, FPE ﬁrst-pass extraction (liver), CL clearance, Vc
volume of distribution
a In silico predicted (ADMETPredictor™ module)
b Estimated by GastroPlus™ on the basis of experimentally
determined pH-solubility proﬁle
cValue calculated on the basis of in vitro measured permeability
(Caco-2 cell line; 24) using permeability converter utility integrated
in GastroPlus™ software
dExperimental values
eDefault GastroPlus™
fLiterature value taken from (7)
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good prediction of gliclazide oral absorption. Although the
percent prediction error for tmax was relatively high (18.22%),
it has to be considered that this value was calculated in
comparison to the mean tmax value estimated for a particular
in vivo observed data set (2). Considering the variable
gliclazide in vivo kinetics (reported mean tmax values after
oral administration of IR tablets varied between 2.3 and 4.5 h
(2,6,16), the simulated value of 3.68 h can be considered as a
reasonable estimate.
The resultant ASF values, adjusted to best ﬁt the
observed plasma concentration–time data for GLK IR
tablets, were lower than GastroPlusTM generated values,
indicating possible inﬂuence of efﬂux transporters on
gliclazide absorption through the small intestine. This
assumption is supported by the results of Al-Salami and
associates revealing that gliclazide is a substrate of the ileal
efﬂux drug transporters Mrp2 and Mrp3 (17,18). The role
of transporters in oral drug absorption have been
emphasized by the introduction of the Biopharmaceutics
Drug Disposition Classiﬁcation System (BDCCS) that
enables predictability of in vivo drug transport,
absorption, and disposition on the basis of drug solubility
and the extent of metabolism (19,20). Regarding
experimentally obtained pH-solubility data and literature-
reported extensive metabolism in liver (2), gliclazide would
be assigned as BDCCS class II drug wherein efﬂux
transporters are expected to affect the extent and rate of
the oral drug absorption.
Parameter sensitivity analysis (data not shown) revealed
that the percent of GLK absorbed (Fa) is rather insensitive to
the variations in PK parameters tested. The PSA also showed
that broad variations in the selected PK parameters affect the
predicted Cmax and tmax, but there were no signiﬁcant
differences observed when these PK inputs were varied in a
range covering literature-reported values (1,6).
GastroPlusTM generated regional absorption distribution
demonstrated that majority of GLK is absorbed in duodenum
and jejunum (69.9%), while the rest of the dose is absorbed in
mid and distal GI regions (Fig. 3). This is in accordance with
solubility results indicating that GLK solubility in proximal
parts of the intestine might not be enough for drug absorption
to be completed in these compartments. However, in mid and
distal GI regions (ileum, caecum), GLK solubility is high
enough for the total amount of remaining undissolved drug to
completely dissolve and, consequently, pass into the systemic
circulation.
In Vitro–In Vivo Correlation
Numerical Convolution. Different virtual dissolution
proﬁles used as inputs for gastrointestinal simulations are
presented in Fig. 4a. The corresponding Cp–time proﬁles
(Fig. 4b), estimated on the basis of the generated GLK-
speciﬁc absorption model, were plotted against the in vivo
observed data in order to develop a level A IVIVC model
(Fig. 5). The obtained correlation coefﬁcients and slopes of
the regression lines are given in Table III.
The results obtained indicated that variations in drug input
kinetics were well reﬂected on the simulated in vivo proﬁles.
However, it is evident that differences observed in vitro were
less pronounced in the predicted PK proﬁles (the simulated
proﬁles b, c, and d overlap). The highest degree of deviation
from the in vivo observed proﬁle was demonstrated for proﬁle a,
representing scenario in which less than 85% of the drug is
dissolved. On the other hand, values of the slope close to unity
as well as high coefﬁcients of correlation indicated the presence
of level A correlation for the proﬁles b, c, e, and d.
Numerical Deconvolution. In an attempt to establish
IVIVC using deconvolution approach, hypothetical in vivo
absorption proﬁle estimated by GastroPlusTM from the in
vivo Cp–time curve (2) was compared with the virtual in vitro
dissolution proﬁles. In order to produce a meaningful
correlation, it was assumed that these proﬁles must not
differ in their morphology. In the case of GLK IR tablets,
the in vitro dissolution proﬁle ran ahead the in vivo
dissolution, so rescaling of the time axis when progressing
Table II. Comparison of Pharmacokinetic Parameters Between
Simulated and In Vivo Observed Data for GLK After Oral
Administration of 80-mg IR Tablets
Parameter Observed Simulated PE (%)
Cmax (μg/ml) 2.98 2.77 7.05
tmax (h) 4.50 3.68 18.22
AUC0→∞ (μg h/mL) 67.15 63.03 6.13
AUC0→t (μg h/mL) 52.40 57.07 −8.92
GLK gliclazide, IR immediate-release, PE prediction error values,
AUC area under the curve Fig. 3. Compartmental absorption of gliclazide
Fig. 2. GastroPlusTM predicted (line) and observed (2) (open square)
mean GLK plasma Cp–time proﬁles following administration of a
single 80-mg gliclazide IR tablet
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from in vitro to in vivo was necessary. IVIVC plot of the
percentage dissolved in vitro versus the percentage absorbed
in vivo is presented in Fig. 6.
The outcomes of deconvolution approach (Table IV) are
in accordance with those obtained by convolution approach.
It was shown that the in vitro proﬁle e (stretched by 12-fold
linear rescaling of the time axis) has the same general shape
(morphology) as the estimated hypothetical in vivo dissolu-
tion proﬁle. However, good correlation was also achieved for
the in vitro proﬁles b, c, and d (as illustrated by the estimated
statistical parameters).
Dissolution Test Requirements
British Pharmacopoeia (BP) gives recommendation for
dissolution test conditions for GLK IR tablets (900 ml of
media pH 7.4, paddle apparatus at 100 rpm), but no
dissolution test requirements have been appointed so far in
BP or other regulatory documents. Regarding the pH-
solubility proﬁle of GLK, the dissolution process at pH 7.4
is expected to be fast and complete (complying with the
hypothetical proﬁle representing “very rapid” dissolution
scenario). Our results suggest that dissolution speciﬁcation of
>85% GLK dissolved in 60 min may be considered as
biorelevant dissolution acceptance criteria for GLK IR
tablets.
Biowaiver Considerations
The most common type of biowaiver adopted by the
regulatory authorities include the application of the BCS-
based scheme (similar or rapid/very rapid dissolution proﬁles
of the test and reference product in pH 1.2, 4.5, and 6.8
media) or the application of IVIVC. In the case of IR dosage
forms, biowaivers may be requested solely for highly soluble
and highly permeable substances (BCS class I) when its drug
product is (very) rapidly dissolving and exhibits similar
dissolution proﬁle to the reference product, while the
IVIVC-based approach has been narrowed down to applica-
tions for extended-release products (15,21,22). Recent sug-
gestions point out that IVIVC-based biowaiver concept could
be extended to some BCS class II drugs under the assumption
that the drug dissolves completely during the GI passage (23).
In the case of highly soluble (BCS class I) drugs, it is
generally accepted that complete dissolution in vivo complies
with very rapid/rapid in vitro dissolution kinetics (15,21).
However, in the case of BCS class II drugs, complete in vivo
dissolution might occur at later time points, allowing wider
biorelevant in vitro dissolution speciﬁcation to be set. This
assumption is supported by the results of the present study
demonstrating that differences in GLK in vitro dissolution
kinetics such as 85% drug dissolved within the 15–60 min
Fig. 5. IVIVC plot for GLK IR tablets (convolution approach)
Table III. Statistical Parameters of the Obtained IVIVC (Convolu-
tion Approach)
In vitro inputs a Value r Value
Proﬁle a 0.440 0.382
Proﬁle b 0.894 0.897
Proﬁle c 0.896 0.910
Proﬁle d 0.898 0.923
Proﬁle e 0.867 0.947
a slope of the regression line, r coefﬁcient of correlation
Fig. 4. Virtual gliclazide dissolution proﬁles (a) and the corresponding simulated in vivo proﬁles, along with the actual in vivo data (2). The
simulated proﬁles b, c, and d overlap (b)
169Gliclazide IR Tablets: Absorption Simulation. IVIVC
time frame would not be reﬂected on in vivo pharmacokinetic
proﬁle.
In order to assess whether dissolution is a rate-limited
factor for gliclazide absorption, dissolution behavior of differ-
ent GLK IR tablets was studied in various pH media (pH 1.2,
4.0, and 7.2). Experimental data for generic tablets commer-
cially available on Serbian market, together with the liter-
ature data for Diamicron tablets (3) are shown in Fig. 7. In
medium pH 4.0, dissolution was slow and incomplete for all
the investigated formulations, presumably due to the low
solubility of gliclazide at pH 3.0–4.2. Although gliclazide
exhibits comparable solubility at pH 1.2 and 7.2, slower
release rate at pH 1.2 (less than 85% of GLK dissolved in
60 min from Glikosan and Diamicron tablets) indicated that
solubility is not a major factor that governs gliclazide
dissolution rate in this medium. According to Hong et al.
(3), slow dissolution at pH 1.2 could be explained by slow
water penetration into the dosage form at this pH. On the
other hand, the release process in pH 7.2 medium was fast
and complete, except in the case of Diprian tablets. Less than
10% gliclazide released into the pH 7.2 buffer within 60 min
indicate that Diprian tablets might correspond to a modiﬁed-
release (MR) formulation. However, further in vivo studies
are needed in order to investigate whether the resultant
plasma concentration–time proﬁle following oral administra-
tion of Diprian tablets resemble the one resulting from typical
MR gliclazide formulation. It should be noted that, regardless
of the favorable dissolution test conditions (high solubility at
pH 7.2, intensive rotational speed of 100 rpm), this medium
was still able to discriminate between different gliclazide
formulations (drug release rates from Glioral and Glikosan
tablets were “very rapid”, while Diamicron tablets complied
with “rapidly” dissolving formulation). In the absence of in
vivo bioequivalence data (gliclazide plasma levels after
administration of Glioral and Glikosan tablets in comparison
to Diamicron tablets were not available), there is not enough
information to conclude whether pH 7.2 media at 100 rpm
would provide biorelevant and discriminatory test conditions
for in vitro evaluation of GLK IR tablets. However, the
present results indicate that GLK solubility and dissolution
from IR tablets are not expected to be the rate-limiting
factors for gliclazide in vivo absorption, and since this is a
Fig. 7. Dissolution proﬁles of generic 80-mg gliclazide tablets
commercially available on Serbian market (experimental data),
together with the literature data for Diamicron 80-mg gliclazide
tablets (3) in different media: pH 1.2 (a), 4.0 (b), and 7.2 (c)
Table IV. Statistical Parameters of the Obtained IVIVC (Deconvo-
lution Approach)
In vitro inputs a Value r Value
Proﬁle a 2.289 0.875
Proﬁle b 1.031 0.894
Proﬁle c 1.056 0.929
Proﬁle d 0.946 0.896
Proﬁle e 1.189 0.999
a slope of the regression line, r coefﬁcient of correlation
Fig. 6. IVIVC plot for GLK IR tablets (deconvolution approach)
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highly permeable drug, there is a rationale to postulate that
biowaiver extension might be applicable in the case of GLK
IR tablets. Additionally, other factors such as the potential
impact of intestinal efﬂux transporters on GLK absorption
should be thoroughly investigated and understood when
considering biowaiver extension.
CONCLUSION
The presented data demonstrate that gastrointestinal
simulation technology can be successfully used to predict GLK
absorption proﬁle. In the present case, both convolution and
deconvolution approaches were successful in establishing a level
A IVIVC. Based on the results obtained by IVIVC in
conjunction with GIST, dissolution speciﬁcation of >85% GLK
dissolved in 60min could be suggested as biorelevant dissolution
acceptance criteria for GLK IR tablets. The dissolution criteria
depicted in this study can be used to develop in vitro method-
ology that would be predictive of drug products in vivo behavior
and that might eventually serve as surrogate for clinical BE
studies (biowaiver) for GLK IR tablets.
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